Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (RINVOQ®▼) for psoriatic arthritis

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 24 - Feb - 2022
Body System:
Red
UPADACITINIB prolonged-release tablets (RINVOQ®▼) for psoriatic arthritis

The Pan Mersey Area Prescribing Committee recommends the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼), by specialists only, for psoriatic arthritis, in accordance with NICE TA768.